The Quebec government recently announced, as part of its budget,
the intended abolishment of the rule known as "BAP-15."
Under the BAP-15 policy, which has been in place since 1994, the
Quebec government would pay the cost of the brand for 15 years for
publicly covered patients, even if a generic competitor entered
onto the formulary before that time. Although the 15-year rule was
put in place with the balancing "best available price
rule" (meaning that the manufacturer's selling price for a
covered product in the province of Quebec could be no more than the
selling price under other provincial plans), so far there has been
no formal announcement of any change to that aspect of the policy
in Quebec. In other words, the most favoured nation type of policy
for Quebec remains in place vis-à-vis pricing of products in
The RAMQ has now issued an Infolettre, dated December 14, 2012,
announcing that as of January 14, 2013, the 15-year rule in respect
of multi-source products will be abolished, and that the mechanism
of annual price increases has also been abolished. Accordingly to
the Infolettre, the prices of all products on the Liste des
medicaments will be maintained at their current level. It is,
however, possible for a manufacturer to submit a lower price.
The pricing and reimbursement landscape for pharmaceutical and
biologic products in Canada is ever-changing. We will be monitoring
developments in the Quebec market, with a view to reporting on
updates as they arise.
Norton Rose Group
Norton Rose Group is a leading international legal practice.
We offer a full business law service to many of the world's
pre-eminent financial institutions and corporations from offices in
Europe, Asia, Australia, Canada, Africa, the Middle East, Latin
America and Central Asia.
Knowing how our clients' businesses work and
understanding what drives their industries is fundamental to us.
Our lawyers share industry knowledge and sector expertise across
borders, enabling us to support our clients anywhere in the world.
We are strong in financial institutions; energy; infrastructure,
mining and commodities; transport; technology and innovation; and
pharmaceuticals and life sciences.
We have more than 2900 lawyers operating from 43 offices in
Abu Dhabi, Almaty, Amsterdam, Athens, Bahrain, Bangkok, Beijing,
Bogotá, Brisbane, Brussels, Calgary, Canberra, Cape Town,
Caracas, Casablanca, Dubai, Durban, Frankfurt, Hamburg, Hong Kong,
Johannesburg, London, Melbourne, Milan, Montréal, Moscow,
Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome,
Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from
associate offices in Dar es Salaam, Ho Chi Minh City and
Norton Rose Group comprises Norton Rose LLP, Norton Rose
Australia, Norton Rose Canada LLP, Norton Rose South Africa
(incorporated as Deneys Reitz Inc), and their respective
On January 1, 2012, Macleod Dixon joined Norton Rose
Group adding strength and depth in Canada, Latin America and around
the world. For more information please visit
Norton Rose will join forces with Fulbright &
Jaworski L.L.P on June 1, 2013, creating Norton Rose Fulbright a
global legal practice with significant depth of expertise across
the USA, Europe, Asia, Australia, Canada, Africa, the Middle East,
Latin America and Central Asia.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
On October 3, 2012, the Minister of Health, the Honourable Leona Aglukkaq, announced the government’s intention to introduce regulations that would govern the submission for and approval of drugs for rare diseases, often termed "orphan" drug products, in Canada.